|
KMID : 1039420190530060347
|
|
Journal of Pathology and Translational Medicine
2019 Volume.53 No. 6 p.347 ~ p.353
|
|
|
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
|
|
Chang Sun-Hee
Park Hyung-Kyu
Choi Yoon-La
Jang Se-Jin
|
|
|
Abstract
|
|
|
Background: Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples.
Methods: Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: <1%, 1%?49%, and ≥50%.
Results: The intraclass correlation coefficient for TPS was 0.902±0.058. Weighted κ coefficient for 3-step assessment was 0.748±0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type.
Conclusions: Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti?PD-1 therapy in NSCLC.
|
|
|
KEYWORD
|
|
|
Programmed cell death-ligand 1, Reproducibility, Observer variation, Immunohistochemistry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|